

If you are in any doubt as regards the contents of this letter, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor or other independent adviser authorised under the Financial Services and Markets Act 2000 if you are in the United Kingdom, or from another appropriately authorised independent financial adviser if you are in a territory outside the United Kingdom. If you have sold or otherwise transferred all of your ordinary shares in Mediclinic International plc, please send this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or transferred only part of your holding of ordinary shares in Mediclinic International plc, you should retain this document and consult the bank, stockbroker or other agent through whom the sale was effected. However, this document should not be forwarded or transmitted into any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

10 June 2022

To: Mediclinic International plc ("**Mediclinic**") shareholders, persons with information rights, and holders of securities.

Announcement regarding possible offer for Mediclinic

On 9 June 2022, a consortium comprising Remgro Limited ("**Remgro**") and MSC Mediterranean Shipping Company SA, acting through its wholly owned subsidiary, SAS Shipping Agencies Services Sàrl, (together the "**Consortium**") announced that it had made a proposal to the board of directors of Mediclinic (the "**Board**") concerning a possible offer (the "**Potential Offer**") to acquire the entire issued and to be issued ordinary share capital of Mediclinic not already owned by Remgro (the "**Proposal**"). Mediclinic made a subsequent announcement later that day confirming it had received the Proposal from the Consortium and that the Board had considered the Proposal and unanimously rejected it, concluding that it significantly undervalued Mediclinic and its future prospects.

In accordance with Rule 2.11 of the City Code on Takeovers and Mergers (the "**Takeover Code**"), we are required to send you the attached copy of the announcement made by the Consortium so that it is readily available to you. We have also attached a copy of the announcement by Mediclinic. A copy of the announcements, and all other information, documents and announcements relating to the Potential Offer, have also been made available on Mediclinic's website at <https://investor.mediclinic.com>. This letter is not to be taken as a summary of the information in the announcements and should not be regarded as a substitute for reading the announcements in full. For the avoidance of doubt, the content of Mediclinic's website is not incorporated into, and does not form part of, this letter.

Although the announcement has put Mediclinic into what is known as an "offer period" under the Takeover Code, there can be no certainty that the Consortium will proceed to make an offer for Mediclinic. A further announcement will be made in due course as appropriate. Shareholders are not required to take any action at this time.

Yours faithfully,



Dame Inga Beale
Chair
Mediclinic International plc

ETHICS LINE AND EMAIL

EMAIL
mediclinic@tip-offs.com

SOUTH AFRICA
TOLL-FREE 0800 005 316

NAMIBIA
TOLL-FREE 0800 003 313
081 91847 (MTC NETWORKS)

HIRSLANDEN
TOLL-FREE 0800 005 316

MEDICLINIC MIDDLE EAST
TOLL-FREE 0800 1 55000

MEDICLINIC INTERNATIONAL PLC
REGISTERED IN ENGLAND AND WALES
COMPANY NUMBER: 08338604

Important Notices

Should you wish to contact Mediclinic regarding administrative matters in view of the announcements, please contact Caroline Emmet in the United Kingdom on +44 (0)333 300 1930 or caroline.emmet@linkgroup.co.uk or Marlene De Beer in South Africa on +27 21 861 1036 or marlene.debeer@mediclinic.com during normal business hours. Please be aware that addresses, electronic addresses and certain other information provided by you for the receipt of communications from Mediclinic may be provided to the Consortium during the offer period as required under Section 4 of Appendix 4 of the Takeover Code.

Responsibility statement

The directors of Mediclinic (the “**Directors**”) accept responsibility for the information contained in this letter relating to Mediclinic. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this letter (including any expressions of opinion) is in accordance with the facts and does not omit anything likely to affect the import of such information.

Right to request hard copies

Our current default is to send you any documents in relation to the Potential Offer that we are required to by hard copy. You may change these communication preferences (or request a hard copy of any information incorporated into such documents by reference to another source) by writing to Computershare Investor Services PLC in the United Kingdom at WebCorres@computershare.co.uk or The Pavilions, Bridgwater Road, Bristol, BS13 8AE, United Kingdom, or by calling 0370 703 6022 if dialling from the UK and +44 370 703 6022 if dialling from abroad, or Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch, 7599 in South Africa at info@mediclinic.com or by calling +27 21 809 6500 during normal business hours.

Disclosure Requirements of the Takeover Code

Under Rule 8.3(a) of the Takeover Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

ETHICS LINE AND EMAIL

EMAIL
mediclinic@tip-offs.com

SOUTH AFRICA
TOLL-FREE 0800 005 316

NAMIBIA
TOLL-FREE 0800 003 313
081 91847 (MTC NETWORKS)

HIRSLANDEN
TOLL-FREE 0800 005 316

MEDICLINIC MIDDLE EAST
TOLL-FREE 0800 1 55000

MEDICLINIC INTERNATIONAL PLC
REGISTERED IN ENGLAND AND WALES
COMPANY NUMBER: 08338604

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT ANY SUCH OFFER WILL BE MADE

FOR IMMEDIATE RELEASE

9 June 2022

Response to press speculation on Mediclinic International plc ("Mediclinic")

Remgro Limited ("Remgro") and MSC Mediterranean Shipping Company SA ("MSC"), acting through its wholly owned subsidiary SAS Shipping Agencies Services Sàrl ("SAS"), note the recent press speculation relating to a potential transaction involving Mediclinic.

Remgro and SAS (together the "Consortium") confirm that on 26 May 2022 the Consortium made a proposal to the Board of Mediclinic regarding a possible cash offer for the issued and to be issued share capital of Mediclinic not already owned by Remgro at a price of 463 pence per share (the "Proposal"). The Consortium is comprised equally of Remgro, Mediclinic's long-term 44.6% shareholder, and SAS.

The Proposal is inclusive of the final dividend of 3 pence per share declared by Mediclinic on 25 May 2022 (the "FY22 Final Dividend"). Subject to approval of the FY22 Final Dividend at the Mediclinic Annual General Meeting and following the FY22 Final Dividend record date which is currently expected to be 5 August 2022, the Proposal shall be reduced by the amount of the FY22 Final Dividend, in which case eligible Mediclinic shareholders will be entitled to retain the FY22 Final Dividend. The closing price of Mediclinic was 373 pence on 25 May 2022, being the last business day before the submission of the Proposal.

The Proposal was rejected by the Mediclinic Board of Directors. The Consortium is considering its position. There can be no certainty that any offer will be made.

Any offer, if made, is likely to be solely in cash. Pursuant to Rule 2.5 of the Code, the Consortium reserves the right to vary the form of consideration at its discretion and/or introduce other forms of consideration such as securities in substitution for all or part of the cash consideration.

The Consortium also reserves the right to make an offer for Mediclinic at any time at a lower value or on less favourable terms:

- a) with the recommendation or consent of the Mediclinic Board;
- b) if a third party announces a possible offer or a firm intention to make an offer for Mediclinic on less favourable terms; or
- c) following the announcement by Mediclinic of a Rule 9 waiver proposal pursuant to the Code or a reverse takeover (as defined in the Code).

The Consortium reserves the right to reduce the terms of its Proposal by the amount of any dividend (or other distribution) which is paid or becomes payable by Mediclinic to its shareholders after the date of this announcement, except in respect of the FY22 Final Dividend.

A further announcement will be made as appropriate.

In accordance with Rule 2.6(a) of the Code, the Consortium is required, by no later than 5.00 p.m. on 7 July 2022, either to: (i) announce a firm intention to make an offer, subject to conditions or pre-conditions if relevant, for Mediclinic in accordance with Rule 2.7 of the Code; or (ii) announce that it does not intend to make an offer for Mediclinic, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline will only be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

Enquiries

Remgro Limited

Mariza Lubbe

Tel: + 27 21 888 3000

MSC / SAS

Giles Broom

Tel: + 41 22 703 9886

Nomura International plc (Lead Financial Adviser to the Consortium)

Adrian Fisk
Ben Lowther
Oliver Donaldson

Tel: + 44 (0)20 7102 1000

Centerview Partners UK LLP (Financial Adviser to Remgro)

Hadleigh Beals
Alexander Elias
Alexander Gill

Tel: + 44 (0)20 7409 9700

Credit Suisse International (Financial Adviser to MSC)

Jens Haas
Ben Deary
Brice Bolinger

Tel: + 44 (0)20 7888 8888

Important Notice

Nomura International plc ("Nomura"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser to the Consortium and no one else in connection with the matters set out in this announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than the Consortium for providing the protections afforded to clients of Nomura nor for giving advice in relation to any matter or arrangement referred to in this announcement.

Centerview Partners UK LLP ("Centerview"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively as financial adviser to Remgro and no one else in connection with the matters set out in this announcement and is not, and will not be, responsible to anyone other than Remgro for providing the protections afforded to clients of Centerview or for providing advice in connection with the subject matter of this announcement or any other matter referred to herein.

Credit Suisse International ("Credit Suisse"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the UK, is acting as financial adviser exclusively for MSC and no one else in connection with the matters set out in this announcement and will not be responsible to any person other than MSC for providing the protections afforded to clients of Credit Suisse, nor for providing advice in relation to the content of this announcement or any matter referred to herein. Neither Credit Suisse nor any of its subsidiaries,

branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Credit Suisse in connection with this announcement, any statement contained herein or otherwise.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Publication on Website

A copy of this announcement will be made available subject to certain restrictions relating to persons resident in restricted jurisdictions on the Remgro and MSC respective websites at www.Remgro.com and www.MSC.com by no later than 12 noon (London time) on the business day following the date of this announcement. The content of these websites are not incorporated into and do not form part of this announcement.

Overseas Jurisdictions

The release, publication or distribution of this announcement in jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about, and observe any applicable requirements. This announcement has been prepared for the purposes of complying with English law and the Code and the information disclosed in this announcement may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1993, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

June 9, 2022

RNS Number : 29950
Mediclinic International plc
09 June 2022

FOR IMMEDIATE RELEASE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. **THERE CAN BE NO CERTAINTY THAT ANY OFFER WILL BE MADE.**

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

9 June 2022

RESPONSE TO POSSIBLE OFFER

The Board of Mediclinic International plc ("Mediclinic" or the "Company") notes the announcement made by the consortium comprising Remgro Limited ("Remgro") and MSC Mediterranean Shipping Company SA, acting through its wholly-owned subsidiary, SAS Shipping Agencies Services Sàrl, (together the "Consortium").

The Board of Mediclinic confirms that, on 26 May 2022, it received an unsolicited and conditional proposal from the Consortium, concerning a possible cash offer to acquire the entire issued and to be issued ordinary share capital of Mediclinic not already owned by Remgro at 460 pence per share plus the Mediclinic proposed final dividend for the financial year ended 31 March 2022 of 3 pence per share (the "Proposal").

The Board of Mediclinic (excluding the Remgro representative) considered the Proposal, together with its advisers, and concluded that it significantly undervalued Mediclinic and its future prospects. Accordingly, on 31 May 2022, the Board of Mediclinic (excluding the Remgro representative) unanimously rejected the Proposal.

There can be no certainty that any offer will be made for the Company.

Shareholders are urged to take no action in relation to the possible offer at this time.

This announcement has been made without the consent of the Consortium.

Any offer for Mediclinic is governed by the City Code on Takeovers and Mergers. Under Rule 2.6(a) of the Code, the Consortium must by not later than 5.00 p.m. on 7 July 2022 either announce a firm intention to make an offer for Mediclinic in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline will only be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

The person responsible for arranging for the release of this announcement on behalf of Mediclinic is Jurgens Myburgh, CFO.

ENQUIRIES

**Mediclinic International
plc**
James Arnold
Head of Investor Relations
ir@mediclinic.com

+44 (0)20 3786 8181

Morgan Stanley (Financial Adviser to Mediclinic)
7425 8000
Matthew Jarman
Tom Perry

+44 (0)20

Anthony Zammit
Obaid Mufti

FTI Consulting (Media enquiries)

Ben Atwell/Ciara Martin - UK

(0)20 3727 1000

Sherryn Schooling - South Africa

(0)21 487 9000

+44

+27

Mediclinic International plc

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: <https://www.mediclinic.com/>

Corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified.

You should contact the Takeover Panel's Market Surveillance Unit on +44 (0) 20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Financial adviser

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the UK is acting as sole financial adviser exclusively for Mediclinic and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.

Website

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Mediclinic's website at <https://investor.mediclinic.com/> by no later than 12 noon (London time) on the business day following the date of this announcement. The content of this website is not incorporated into, and does not form part of, this announcement.

Rule 2.9

In accordance with Rule 2.9 of the Code, as at the date of this announcement, Mediclinic's issued share capital comprises 737,243,810 ordinary shares of GBP0.10 each held outside treasury (ISIN: GB00B8H8Z88).

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

LEI: 2138002S5BSBIZTD5I60

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

OFDGRGDLGGGDGDC